Compare Duolingo Inc (DUOL) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Dyne Therapeutics Inc. Common Stock — how do they compare? Duolingo Inc trades at $138.28 (market cap $6.55B), while Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B). The key difference: Duolingo Inc is far larger — about 2.3× Dyne Therapeutics Inc. Common Stock's market cap, and Duolingo Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 138 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DUOL | DYN | |
|---|---|---|
Market Cap | $6.55B | $2.86B |
Volume | 767,658 | 3,341,579 |
Sector | Technology | Health |
52-Week High | $341.08 | $26.78 |
52-Week Low | $90.03 | $14.60 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $5.33B | $2.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $139.73, down 5.42% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental performance with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a robust 39.9% profit margin. Recent earnings beats and analyst consensus of $142.50 price target suggest underlying strength despite recent price weakness. Technical indicators show a bullish moving average signal with neutral oscillators, while institutional sentiment remains mixed with notable insider selling activity.
Duolingo presents a compelling growth story with exceptional profitability metrics and consistent earnings outperformance. The primary investment opportunity lies in the company's AI-driven platform expansion and strong user growth momentum. Key risks include CEO share liquidations, competitive pressures in edtech, and valuation concerns at current levels. The stock's current discount to consensus target offers potential upside if execution continues.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
